Online Inquiry

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.


Histiocytic and Dendritic Cell Neoplasms

In the world of oncology, the study of rare diseases such as histiocytic and dendritic cell neoplasms present unique challenges. At our company, we are dedicated to pushing the boundaries of scientific research and developing innovative therapies to combat these complex diseases.

Overview of Histiocytic and Dendritic Cell Neoplasms

Histiocytic and dendritic cell neoplasms are a group of rare and heterogeneous diseases characterized by the abnormal proliferation and accumulation of histiocytes and dendritic cells. These cells, which play crucial roles in immune responses, become dysregulated, leading to the development of tumors in various tissues. The pathogenesis of histiocytic and dendritic cell neoplasms is multifactorial and not yet fully elucidated. However, it is believed that the transformation of precursor cells, such as monocytes and dendritic cell precursors, contributes to the development of these neoplasms.

Classification of Histiocytic and Dendritic Cell Neoplasms

  • Langerhans cell and other dendritic cell neoplasms
    • Langerhans cells neoplasms
  • Langerhans cell histiocytosis
  • Langerhans cell sarcoma
  • other dendritic cell neoplasms
  • indeterminate dendritic cell tumor
  • interdigitating dendritic cell sarcoma
  • Histiocyte/macrophage neoplasms
    • juvenile xanthogranuloma
    • Erdheim-Chester disease
    • Rosai-Dorfman Disease
    • ALK-positive histiocytosis
    • histiocytic sarcoma
Fig.1 Representative histological images of histiocytic and dendritic cell neoplasms.Fig.1 Representative histological images of histiocytic and dendritic cell neoplasms. (Okada, Kanae, et al., 2021)

Potential Targets of Histiocytic and Dendritic Cell Neoplasms

  • ABL1
  • AFF1
  • AKT1
  • AKT2
  • AKT3
  • ALK
  • ARAF
  • ASXL1
  • BCR
  • BRAF
  • CCND1
  • CCND2
  • CCND3
  • CCNE1
  • CCNE2
  • CDK2
  • CDK4
  • CDK6
  • CDKN1A
  • CDKN1B
  • CDKN2A
  • CRKL
  • DEK
  • ELL
  • EZH2
  • FGFR1
  • FGFR2
  • FGFR3
  • FGFR4
  • FLT3
  • HRAS
  • KMT2A
  • KRAS
  • MAP2K1
  • MAP2K2
  • MAP2K4
  • MAP3K1
  • MAPK1
  • MLF1
  • MLLT1
  • MLLT10
  • MLLT3
  • MLLT4
  • MTOR
  • NF1
  • NPM1
  • NRAS
  • NRIP3
  • NTRK1
  • NTRK2
  • NTRK3
  • NUP214
  • PIK3CA
  • PIK3CG
  • PIK3R1
  • PIK3R2
  • PTEN
  • RAF1
  • RB1
  • ROS1
  • RPN1
  • RUNX1
  • SRC
  • TP53
  • TSC1
  • TSC

Therapy Development of Histiocytic and Dendritic Cell Neoplasms

Targeted Therapy

Targeted therapies aim to inhibit specific molecular alterations that drive the growth and survival of neoplastic cells. For example, inhibitors of the BRAF pathway, such as vemurafenib and dabrafenib, have shown efficacy in treating Langerhans cell histiocytosis with BRAF mutations.


Immunotherapies harness the power of the immune system to recognize and eliminate cancer cells. Checkpoint inhibitors, such as pembrolizumab and nivolumab, hold promise in subsets of histiocytic and dendritic cell neoplasms by enhancing immune responses against tumor cells.

Our Services

At our company, we are at the forefront of histiocytic and dendritic cell neoplasm diagnostics and therapy development. Our dedicated team of scientists and researchers works tirelessly to identify novel therapeutic targets and develop innovative drugs to combat these diseases. Our cutting-edge drug development services encompass target identification and validation, hit-to-lead optimization, preclinical pharmacology, toxicology, and pharmacokinetic analysis.

Our Therapy Development Platforms

Furthermore, we provide comprehensive animal model development services, crucial for preclinical studies and the evaluation of potential therapies. By utilizing state-of-the-art technologies and utilizing our extensive expertise, we strive to accelerate the translation of promising therapies from bench to bedside.

If you are interested in our services, please feel free to contact us for more details and quotation information of related services.


  • Okada, Kanae, et al. "Histiocytic and dendritic cell neoplasms: Reappraisal of a Japanese series based on t (14; 18) and neoplastic PD‐L1 expression." Pathology International 71.1 (2021): 24-32.
  • Pan, Zenggang, and Mina L. Xu. "Histiocytic and dendritic cell neoplasms." Surgical Pathology Clinics 12.3 (2019): 805-829.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Related Disease Solutions

Copyright © Protheragen. All rights reserves.